PIONEERING TREATMENTS FOCUSED ON COUNTERACTING HEART DYSFUNCTION
Cytokinetics is developing CK-136 (AMG 594), an investigational, novel, selective, oral, small molecule cardiac troponin activator, as a potential treatment for people with heart failure and other diseases.
In preclinical models, CK-136 has been shown to increase the ability of the heart to contract by binding to cardiac troponin through an allosteric mechanism that sensitizes the cardiac sarcomere to calcium. Similar to cardiac myosin activation, preclinical research has shown that cardiac troponin activation does not change the calcium transient of cardiac myocytes.
A Phase 1 study of CK-136 is now complete with data analyses ongoing. Cytokinetics is continuing to evaluate potential indications for CK-136 beyond HFrEF.